Tarsus Pharmaceuticals, Inc. Quarterly Operating Income (Loss) in USD from Q3 2019 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Tarsus Pharmaceuticals, Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q3 2019 to Q3 2024.
  • Tarsus Pharmaceuticals, Inc. Operating Income (Loss) for the quarter ending September 30, 2024 was -$25.2M, a 38.5% increase year-over-year.
  • Tarsus Pharmaceuticals, Inc. Operating Income (Loss) for the twelve months ending September 30, 2024 was -$141M, a 23.6% decline year-over-year.
  • Tarsus Pharmaceuticals, Inc. annual Operating Income (Loss) for 2023 was -$143M, a 128% decline from 2022.
  • Tarsus Pharmaceuticals, Inc. annual Operating Income (Loss) for 2022 was -$62.7M, a 416% decline from 2021.
  • Tarsus Pharmaceuticals, Inc. annual Operating Income (Loss) for 2021 was -$12.2M, a 55% increase from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$141M -$25.2M +$15.8M +38.5% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-13
Q2 2024 -$156M -$33.3M -$481K -1.47% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-08
Q1 2024 -$156M -$37.7M -$12.7M -51% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-08
Q4 2023 -$143M -$44.5M -$29.4M -195% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-27
Q3 2023 -$114M -$40.9M -$18M -78.7% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-13
Q2 2023 -$95.7M -$32.8M -$27.6M -528% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-08
Q1 2023 -$68.1M -$25M -$5.43M -27.8% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-08
Q4 2022 -$62.7M -$15.1M -$613K -4.24% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-27
Q3 2022 -$62.1M -$22.9M -$7.2M -45.9% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-09
Q2 2022 -$54.9M -$5.22M -$12.5M -172% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-10
Q1 2022 -$42.4M -$19.5M -$30.2M -282% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-09
Q4 2021 -$12.2M -$14.4M -$2.97M -25.9% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-17
Q3 2021 -$9.19M -$15.7M -$5.56M -54.9% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-09
Q2 2021 -$3.62M $7.28M +$10.5M Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-11
Q1 2021 -$14.2M $10.7M +$12.8M Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-11
Q4 2020 -$27M -$11.5M Oct 1, 2020 Dec 31, 2020 10-K 2022-03-14
Q3 2020 -$10.1M -$9.51M -1502% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-10
Q2 2020 -$3.26M Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-05
Q1 2020 -$2.12M Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-11
Q3 2019 -$633K Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-25
* An asterisk sign (*) next to the value indicates that the value is likely invalid.